bmiMD sermorelin review: monthly figures and prepaid totals.

The pricing cards show both rates and totals

The injection page displayed $139 for a one-month option, $119 per month with a $357 three-month total, and $99 per month with a $594 six-month total. Those longer-plan figures are monthly equivalents for a larger commitment, not automatically permission to pay only the smaller amount each month.

Use the total when deciding whether a plan fits the budget. Ask whether it is charged upfront, whether a financing option changes the payment arrangement, and what happens if the prescription changes before the prepaid period ends. The cost guide explains why rate, charge frequency, and supply period are separate fields. We did not verify the payment screen or the terms attached to any financing option.

One billing sentence needs reconciliation

Elsewhere, the page described a $139 monthly starting figure with quarterly billing and monthly shipping. That wording is not a clean match for the three-month pricing card. Rather than silently selecting the most attractive interpretation, this review flags the inconsistency.

Ask bmiMD to confirm the exact plan, charge due today, renewal amount, shipment schedule, and cancellation deadline in writing. Save the answer with the order details. A support clarification can resolve a confusing page, but it should happen before a patient relies on an assumed price. Our subscriptions-and-refunds guide explains why a shipment schedule and a billing schedule can differ even when both are described using monthly language.

The eligibility refund statement has a specific scope

The page describes a refund if the clinical team determines that a person is not eligible for the program. That statement should not be expanded into a promise that all unused medication, prepaid months, or dissatisfaction after dispensing will be refunded.

Ask how ineligibility is handled, how long any refund takes, and which rules apply after a prescription has been prepared or shipped. Also ask what happens if an initially suitable treatment later becomes inappropriate or produces no meaningful benefit. Those are different situations. Keep the financial conversation separate from medical instructions about stopping. The long-term-use guide explains why both parts of the plan need attention.

Do not let broad marketing override the clinical disclaimer

The page discusses wellness outcomes, but it also states that its clinicians do not intend to prescribe the treatment for anti-aging, bodybuilding, or athletic performance. A prospective patient should take that limitation seriously rather than assume a promotional image defines eligibility.

Describe the actual symptoms and medical history accurately. The clinician should explain the diagnosis or treatment rationale and whether further assessment is needed. The muscle-growth article separates research endpoints from bodybuilding claims, and the after-50 guide explains why normal aging does not automatically establish growth hormone deficiency. A transparent assessment may appropriately lead away from sermorelin.

Clarify the product and the follow-up arrangement

The official injection page and help center establish an advertised injection program. Readers searching for bmiMD tablets should verify the currently offered route and selected product separately rather than applying injection details to another preparation. We did not verify a complete tablet checkout during this review.

Ask for the pharmacy identity, active ingredients, label instructions, and storage conditions. The page advertises clinician access and recurring delivery, but we did not test response times or fulfillment. A useful care plan should explain laboratory decisions, how to report adverse effects, and when benefit is reassessed. Read tablets versus injections and the pharmacy-check guide before treating route or quality claims as settled.

A lower rate can be a larger decision

A six-month commitment can reduce a displayed monthly equivalent while increasing the amount at stake before the patient knows whether treatment is worthwhile. That tradeoff should be considered alongside the clinician's reassessment schedule, not only the discount.

Ask whether the prescription is reviewed during the prepaid period and what happens to future shipments if it is changed or stopped. Confirm whether a monthly shipment represents one portion of an already-paid order or a new charge. The page contains enough competing billing phrases that relying on an assumption would be unwise. A written plan summary should connect the amount charged, the medication supplied, and the renewal date in one understandable explanation.

Confirm that any answer applies to the current selected plan, rather than an earlier promotion or a different product.

Who should include bmiMD in the comparison?

bmiMD is relevant for someone comparing an injection program with several commitment lengths and who is willing to resolve the billing inconsistency before purchase. The page's explicit totals are useful, but a lower monthly equivalent should be weighed against the size and flexibility of the commitment.

Compare CoreAge Rx, MaleMD, and Eden using the same period of care. CoreAge Rx receives promotional first placement here, not an evidence-based claim of better clinical results. For every option, prioritize an understandable medical rationale, exact formulation, total cost, and clear follow-up. Do not let a longer discounted subscription determine the duration of treatment before the clinician has established whether continued use is worthwhile.

The CoreAge Rx versus bmiMD comparison explains why matching monthly figures can describe different commitments.